source
- BlossomHill and Latigo Biotherapeutics raise over 30% beyond IPO targetsTwo emerging biotech companies surpassed their initial public offering expectations on Friday, with both BlossomHill Therapeutics and Latigo Biotherapeutics raising at least 30% more capital than p…
- Latigo Biotherapeutics raises $345.6M in IPO to fund non-opioid pain drug pipelineLatigo Biotherapeutics, a Los Angeles-based biotech focused on non-opioid ion-channel-blocking pain therapies, completed an initial public offering on Thursday. The company sold 19.2 million share…